Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-420 dose-escalation and proof-of-concept study in transfusion-dependent thalassemia or low-risk myelodysplastic syndromes
PACTR202605851690765Phase 2Not yet recruiting
- Sponsor
- Pharmacosmos
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of petadeferitrin in Thalassaemia and myelodysplastic syndrome (MDS), sponsored by Pharmacosmos. Primary endpoint: Safety and tolerability of ascending doses of SP-420 after 12 weeks treatment. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
petadeferitrin
03
Conditions
Thalassaemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on PACTR202605851690765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605851690765.